EGFR-TKI versus chemotherapy for Asians with previously untreated advanced non-small cell lung cancer: a meta-analysis - EGFR-TKIs versus chemotherapy

Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University, Hatanodai, 1-5-8, Shinagawa-ku, Tokyo, 142-8666, Japan0 个研究点目标入组 1,000 人开始时间: 2017年7月31日最近更新: 2023年10月17日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 1,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Others,meta-analysis etc

入排标准

年龄范围: 20years-old 至 75years-old（—）
性别: All

入选标准

未提供

排除标准

•case-control, cohort, and non-blind clinical trials

研究者

发起方

Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University, Hatanodai, 1-5-8, Shinagawa-ku, Tokyo, 142-8666, Japan

相似试验

尚未招募

不适用

Adjuvant Chemotherapy With or Without Intercalated IcotinibCarcinoma, Non-Small-Cell Lung

NCT03983811Nanfang Hospital, Southern Medical University174

Unknown

2 期

Chemotherapy of NSCLC With or Without IcotinibCarcinoma, Non-Small-Cell Lung

NCT02430974Nanfang Hospital, Southern Medical University50

已完成

2 期

Chemotherapy with EGFR-tyrosine kinase inhibitor (EGFR-TKI) or chemotherapy alone in elderly patients with advanced NSCLC with acquired resistance to EGFR-TKI (NEJ017)on-small cell lung cancer

JPRN-UMIN000008364orth East Japan Study Group100

Unknown

3 期

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCEGFR Gene Mutation

NCT02886195Fujian Cancer Hospital120

已完成

2 期

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual ProgressionLung AdenocarcinomaEGFR Activating Mutation

NCT03544814Shanghai Chest Hospital99